标题：小细胞肺癌化疗耐药的分子机制研究进展

      作者：蔡凯尔 1，谢志龙 1，刘迎澳 1 综述 孙艳芹 2，熊英环 2 审校    1.广东医科大学第二临床医学院，广东 东莞 523820；2.广东医科大学病理学系，广东 东莞 523820

      卷次： 2022年33卷16期

      【摘要】 小细胞肺癌是一种高度侵袭性的低分化神经内分泌癌，在恶性肿瘤中的致死率居首位。一直以来，小细胞肺癌的临床治疗以化疗为主，但由于患者容易产生化疗耐药性而导致化疗失败，预后极差，患者生存率很低。因此，小细胞肺癌的化疗耐药研究对提高患者生存预后至关重要。本文对小细胞肺癌化疗耐药的研究进展进行综述，以期寻找避免化疗耐药的干预策略，改善小细胞肺癌患者的临床结局。
      【关键词】 小细胞肺癌；化疗耐药；干预策略；分子机制；研究进展
      【中图分类号】 R734.2 【文献标识码】 A 【文章编号】 1003—6350（2022）16—2145—03

Research progress on molecular mechanism of chemo-resistance of small-cell lung cancer.
CAI Kai-er 1, XIEZhi-long 1, LIU Ying-ao 1, SUN Yan-qin 2, XIONG Ying-huan 2. 1. The Second Clinical Medical School, GuangdongMedical University, Dongguan 523820, Guangdong, CHINA; 2. Department of Pathology, Guangdong Medical University,Dongguan 523820, Guangdong, CHINA【Abstract】 Small-cell lung cancer (SCLC) is a highly invasive and poorly differentiated neuroendocrine cancer,which ranks first in the mortality of malignant tumors. For a long time, the clinical treatment of small cell lung cancer ismainly based on chemotherapy, but due to the patients's tendency to chemotherapy resistance and lead to chemotherapyfailure, the prognosis is extremely poor and the survival rate of patients is very low. Therefore, the research on chemo-resis-tance of small-cell lung cancer is critical to improving the survival and prognosis of patients. This paper will review the re-search progress of chemo-resistance of SCLC to find intervention strategies and improve the clinical outcome of patients.
      【Key words】 Small-cell lung cancer (SCLC); Chemo-resistance; Intervention strategies; Molecular mechanism;Research progress　　　·综述·doi:10.3969/j.issn.1003-6350.2022.16.028基金项目：国家自然科学基金(编号：81702285)；广东省基础与应用基础研究基金项目(编号：2021B1515140067)；广东医科大学大学生创新实验项目(编号：ZZDS007)；国家级大学生创新创业训练计划项目(编号：202110571008、202110571011)